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Aim: To determine the cardiovascular risk (CVR) in patients with rheumatoid arthritis (RA) and its correlation with disease activity
and functional ability by using the Framingham risk score (FRS) and to compare the CVR of the RA patients with the control group
with the help of the FRS.
Materials and methods: Seventy-four RA patients, who were in conformity with the criteria of the American College of Rheumatology,
were included in this study at Bezmialem Vakıf University Hospital. A total of 39 subjects without inflammatory arthritis were included
as the control group. The FRS was calculated by evaluating age, smoking habits, diabetes, cholesterol and blood pressure measurements.
The disease activity score-28 (DAS-28) and the health assessment questionnaire (HAQ-DI) were applied to the RA patients.
Results: We could not find any significant difference between the case and control groups in terms of FRS. The means of erythrocyte
sedimentation rate (ESR) and blood pressure of participants in the study group were significantly higher than those of the control group.
There was not any significant difference in terms of C-reactive protein (CRP) and cholesterol levels between the groups. DAS-28, HAQDI, CRP, ESR, and disease duration were not significantly correlated with FRS.
Conclusion: For patients who have inflammatory arthritis, new risk score calculation that consists of other disease-specific risk factors,
in addition to traditional ones, is needed.
Key words: Rheumatoid arthritis, cardiovascular risk, functional insufficiency, disease activity

1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease associated with increased mortality and decreased
life expectancy; it affects approximately 1% of the overall
population. Standardized mortality rates vary from
1.28 to 3.0 (1). Increased mortality rates observed in
RA result from increased incidences of cerebrovascular
atherosclerosis and coronary arterial disease. Indeed,
a correlation was demonstrated between the risk for
mortality and cardiovascular disease (CVD) in seropositive
RA patients. RA is considered an independent risk factor
for multiple coronary arterial disease. As well as affecting
mortality, CVD also leads to considerable morbidity (2).
In the literature, patients with RA were reported to have
a higher risk for CVD compared to the overall population
(3). In this study we aimed to investigate the correlation
between functional disability and disease activity and
CVR in patients with RA.
RA is a multisystemic disease with unknown causes.
Despite its several systemic symptoms, the most prominent
* Correspondence: profguler@yahoo.com

feature of RA is often continuous inflammatory synovitis,
which involves the peripheral joints symmetrically. It is
approximately 3-fold more common in women compared
to men. RA is a disease that is observed throughout the
entire world and it can affect any race (4). Microvascular
damage and increased number of cells that surround the
synovium seem to be the earliest lesions in the rheumatoid
synovitis. Mild musculoskeletal symptoms such as insidious
lethargy, loss of appetite, widespread weakness, and pain
are observed in approximately two-thirds of the patients. In
general, specific symptoms appear gradually. Established
RA occurs when numerous joints, especially hands, wrists,
knees, and feet, are involved symmetrically (4). RA is a
systemic disease with several nonarticular symptoms (5).
Rheumatoid vasculitis and pleuropulmonary findings are
observed in patients with severe RA (6). Heart disease that
is related to the rheumatoid process is clinically rare (7,8)
RA is not only a disease that restricts the joint
movements by leading to joint damage and permanent
pain, but it is also a disease that triggers the formation
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of atherosclerotic plates and results in early ischemic
CVD and early death (9). The mortality due to CVD
is high in patients with RA (10). In previous studies, it
was demonstrated that noncoronary atherosclerosis and
coronary calcification were more intensive in patients with
RA when compared to age- and sex-matched controls (11).
The grade of the inflammation is correlated with the risk
for CVD in RA. Therefore, the treatment for inflammatory
disease is thought to decrease this excessive risk. The
treatment for RA was shown to decrease the inflammation
and to regulate all lipid profiles (12).
The Framingham Heart Study was conducted on a
large group of patients who neither developed obvious
CVD symptoms nor had heart attack or stroke. The
group was followed-up with for a long period and the
aim was to determine the contribution of common
factors or characteristics to the occurrence of CVD. The
Framingham risk score (FRS) is a widely studied indicator
to determine the CVR in the overall population. It utilizes
age, sex, smoking status, blood pressure, and cholesterol
levels of the patients. The FRS categorizes 10-year CVR in
3 categories: as low-risk (<10% in 10 years), moderate risk
(10%–20%), and high-risk (>20%).
2. Materials and methods
The study was conducted in the Department of Physical
Therapy and Rehabilitation of Bezmialem Vakıf University
between 2008 and 2009. A total of 74 patients who had
been diagnosed with RA, according to 1987 American
College of Rheumatology classification criteria, were
included in the study. As a control group, we included
patients who were diagnosed with mechanical low back
pain, lumbar discal hernia, and lumbar spondylosis. Ethics
board approval of the study was obtained from the local
ethics board committee of our hospital. All patients who
participated in the study signed informed consent forms.
For all patients, demographics (age, sex, weight, height)
were recorded. Body mass index (BMI) of the patients
was calculated. Systolic and diastolic arterial blood
pressures of the patients were measured after they rested
for 15 min. The starting date of the symptoms and the
date of RA diagnosis were recorded. The drugs used after
the diagnosis and the existing therapies were recorded.
For the patients with RA and for the control group, the
presence of diabetes, hypertension, dyslipidemia, CVD,
and other systemic diseases and the drugs used were
recorded. The patients were asked whether their first- and
second-degree relatives had hypertension, diabetes, or
cerebrovascular and cardiovascular diseases. Information
about smoking and exercise habits were obtained from
personal interviews with the patients. In all the subjects,
the blood samples were drawn in the morning, following a
13-h fasting period. In the blood analyses, complete blood
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count, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), total cholesterol, triglyceride (TG), highdensity lipoprotein (HDL), and low density lipoprotein
(LDL) were investigated. Rheumatoid factor (RF) and
anticyclic citrullinated peptide (anti-CCP) values were
also investigated in the patients with RA.
The disease activity score-28 (DAS-28) is a scoring
system used to evaluate disease activity in patients with
RA. The DAS-28 is calculated using a formula that contains
the following parameters: ESR (or CRP), visual analogue
scale (VAS; the patient grades his/her pain on a scale of
100 mm), the number of swollen joints (determined by
the number of the joints involved), and the number of
tender joints. For this purpose, in the examination of
the joints, tenderness and swelling were evaluated in the
right and left shoulders, right and left elbows, right and
left wrists, 10 metacarpophalangeal joints (right and
left), 10 interphalangeal joints (right and left), and right
and left knees. DAS-28 scores below 2.6 were considered
as remission, DAS-28 scores between 2.6 and 3.2 as low
clinical activity, DAS-28 scores between 3.2 and 5.1 as
moderate clinical activity, and DAS-28 score above 5.1 as
high clinical activity (10).
In evaluating the daily-life functional status of the
patients in rheumatology practice, the most commonly
used method is the ‘Health Assessment Questionnaire
Disability Index’ (HAQ-DI). The HAQ-DI evaluates the
level of functional ability of the patient. It contains 20
questions within 8 categories, named dressing, lifting off,
eating, walking, body care, lying, grasping, and actions.
The scores between 0 and 1 are classified as mild and
moderate functional disability, the scores between 1 and 2
are classified as moderate and severe functional disability,
and the scores between 2 and 3 are classified as very severe
functional disability (10).
In the evaluation form for CVR, all the patients were
questioned regarding sex, birth date, smoking habits,
alcohol consumption, the presence or absence of diabetes,
detailed diet habits, familial history of heart disease, and
physical activity. Other questions included whether the
participants had been previously diagnosed with CVD
or whether the patients experienced chest pain at rest or
during exercise. Additionally, the subjects were questioned
about hypertension and dyslipidemia drugs.
The FRS is one of a number of scoring systems used to
determine an individual’s chances of developing CVD. The
FRS is used to estimate the 10-year CVR of an individual.
The FRS is based on data obtained from the Framingham
Heart Study. CVR scoring systems give an estimate of
the probability that a person will develop cardiovascular
disease within the next 10 years. They also indicate who
is most likely to benefit from prevention, since they give
an indication of who is most likely to develop CVD. For
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this reason, CVR scores are used to determine who should
be offered preventive drugs, such as drugs to lower blood
pressure and drugs to lower cholesterol levels.
In the patients with RA and in the controls, the FRS
was calculated on the framinghamstudy.org website
using parameters such as hypertension, high cholesterol,
smoking, obesity, diabetes, and physical inactivity, as well
as other factors such as triglyceride and HDL cholesterol
levels, age, sex, and psychosocial problems. The results were
divided into 3 categories: low risk (<10% within 10 years),
moderate risk (10%–20%), and high risk (>20%). Since
1948, the participants have been periodically evaluated
every 2 years based on a detailed medical history, physical
examination, and laboratory tests. The participants in the
Framingham study were closely evaluated for many years
and important data were obtained regarding the effects of
important CVR factors.
Statistical analyses were performed using statistical
software. While descriptive statistics (frequency,
percentage, mean, and standard deviation) were used
to evaluate the study results, the Pearson chi-square test
was used to compare qualitative data. Quantitative data
were compared using the Mann–Whitney U test when
there were 2 groups and using the Kruskal–Wallis test
in the presence of more than 2 groups. To determine the
correlation between the quantitative results, Spearman
correlation analysis was used. The results were evaluated as
2-sided, at a 95% confidence interval and at a significance
level of P < 0.05.

3. Results
While the age of the patients ranged between 28 and
72 years in the patient group, it varied between 40 and
74 years in the control group. Fifty-eight (78.4%) of the
patients were women and the remaining 16 (21.6%) were
men. For the control group, there were 38 (97.4%) women
and there was only 1 man (2.6%) (Table 1). Mean age of the
patients was significantly lower than that of the controls (P
< 0.05). There was not a statistically significant difference
between the patients and the controls in terms of weight,
height, and BMI (P > 0.05).
For the subjects of the case group, the distribution of
duration of treatment, duration of disease, and duration
of treatment delay is shown in Table 2. FRS findings and
their distributions for case and control groups are given in
Tables 3 and 4. The difference of FRS was not statistically
significant between the case and control groups (P > 0.05).
The laboratory findings of the case and control groups are
given in Table 5.
Of the subjects in the patient group, 41 (55%) were
RF-positive and 33 (45%) were RF-negative, whereas 41
(55%) were anti-CCP–positive and 33 (45%) were antiCCP–negative.
Mean values of ESR, systolic blood pressure, and
diastolic blood pressure were significantly higher in the
subjects of the case group compared to the controls (P <
0.05). The rates of CVD and familial history of CVD are
given in Table 6. The familial history of DM, HT, and

Table 1. Demographic characteristics of case and control groups.
Case

Control

P

Age (mean ± SD)

51.10 ± 10.16

56.05 ± 7.33

0.013

Weight, kg (mean ± SD)

74.29 ± 14.46

74.72 ± 9.60

0.897

Height, cm (mean ± SD)

157.6 ± 06.76

155.39 ± 5.66

0.114

BMI (mean ± SD)

30.03 ± 6.14

30.92 ± 3.37

0.277

Table 2. The distribution of duration of treatment, duration of disease, and duration of
treatment delay for the patients.
n = 74

Mean ± SD

Min–max

Duration of treatment (years)

5.95 ± 6.78

0 –29

Duration of disease (years)

8.64 ± 7.76

1–33

Duration of treatment delay (years)

2.69 ± 4.78

0–29

Table 3. FRS findings of the case and control group patients.

FRS (mean ± SD)

Case

Control

P

0.039 ± 0.051

0.027 ± 0.028

0.741
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Table 4. FRS distribution of the case and control groups.

Control, n (%)

Case, n (%)

Low FRS

22 (57)

Medium FRS

13 (33)

High FRS

4 (10)

Low FRS

36 (49)

Medium FRS

22 (30)

High FRS

16 (21)

Table 5. Laboratory findings of the case and control groups.
(Mean ± SD)

Case

Control

P

CRP

0.59 ± 0.72

0.52 ± 0.42

0.305

ESR

33.54 ± 19.03

17.97 ± 10

0.014

Thrombocytes

283.05

270.1 ± 65.02

0.428

Total cholesterol

209.3 ± 35.66

215.13 ± 28.93

0.313

HDL

57.04 ± 14.65

61.97 ± 18.03

0.225

VLDL

26.10 ± 11.34

26.21 ± 12.22

0.973

LDL

126.2 ± 34.80

128.79 ± 29.25

0.491

Triglyceride

131.03 ± 56.11

129.71

0.837

SKB

140.8 ± 25.40

129.23 ± 18.16

0.013

DKB

86.28 ± 14.24

76 ± 9.42

0.012

± 70.30

± 61.24

Table 6. CVD and family history of CVD.

Angina
Prior heart attacks
Prior angiography
Prior stents
Prior bypass
Medication for heart disease
A family history of heart disease or
heart attacks
CVD in the family

922

Case, n (%)

Control, n (%)

Yes

6 (8.1)

5 (12.8)

No

68 (91.9)

34 (87.2)

Yes

2 (2.7)

0 (0)

No

72 (97.3)

39 (100)

Yes

2 (2.7)

5 (12.8)

No

72 (97.3)

34 (87.2)

Yes

74 (100)

39 (100)

No

1 (1.4)

1 (2.6)

No

73 (98.6)

38 (97.4)

Yes

6 (8.1)

5 (12.8)

No

68 (91.9)

34 (87.2)

Yes

33 (44.6)

21 (53.8)

No

33 (44.6)

21 (53.8)

Yes

19 (25.7)

17 (43.6)

No

55 (74.3)

22 (56.4)

P
0.422
0.300
0.034
0.642
0.422
0.349
0.052
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dyslipidemia for the patient group and the control group
can be found in Table 7.
For the subjects in the patient group, the number of the
patients who had previously underwent an angiography
was significantly lower compared to the controls (P < 0.05).
For the subjects of patient group and the controls, smoking
and exercise habits are seen in Table 8. DAS-28 and HAQDI scores of the patient group are given in Table 9.
For the subjects in the case group and the controls, the
effect of the use of dyslipidemia therapy on the FRS was not

statistically significant (P > 0.05). For the patient group, the
correlation of the FRS with DAS-28, HAQ-DI, CRP, ESR,
treatment duration, disease duration, the correlation of
steroid use with FRS, and the correlation of RF positivity
and anti-CCP positivity with the FRS were not statistically
significant (P > 0.05). The correlation of DAS-28 scores with
the FRS in the case group is seen in Table 10. The correlation
between the FRS and DAS-28 scores observed in the subjects
of the case group was not statistically significant (P > 0.05).
Table 11 shows the HAQ-DI scores of the patient group.

Table 7. DM, hypertension, and dyslipidemia findings and family histories of the case and control groups.

DM
Treatment of DM
A family history of DM
HT
Medication of HT
Dyslipidemia
Medication for dyslipidemia

Case, n (%)

Control, n (%)

Yes

8 (10.8)

7 (18)

No

66 (89.2)

32 (82)

Yes

7 (9.5)

7 (17.9)

No

67 (90.5)

32 (82.1)

Yes

37 (50)

14 (35.9)

No

37 (50)

25 (64.1)

Yes

24 (32.4)

14 (35.9)

No

50( 67.6)

25 (64.1)

Yes

20 (27)

14 (35.9)

No

54 (73)

25 (64.1)

Yes

11 (14.9)

7 (17.9)

No

63 (85.1)

32 (82.1)

Yes

5 (6.8)

5 (12.8)

No

69 (93.2)

34 (87.2)

P
0.288
0.193
0.152
0.711
0.328
0.670
0.281

Table 8. Smoking and exercise habits of the case and control groups.

Smoking habit

Exercise habit

Case, n (%)

Control, n (%)

Yes

14 (19)

10 (26)

No

60 (81)

29 (74)

Case, n (%)

Control, n (%)

Yes

23 (31)

11 (28.2)

No

51( 69)

28 (71.8)

P
0.406
P
0.717

Table 9. Findings of the DAS-28 and HAQ-DI results for the case group.
n = 74

Mean ± SD

Min–max

DAS-28

3.855 ± 1.224

0.480–6.88

HAQ-DI

0.642 ± 0.705

0.000–2.75
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Table 10. DAS-28 findings of the case group and their relationship with the FRS.
FRS
DAS-28

N

Mean ± SD

Inactive (<3.2)

22

0.041 ± 0.038

Mean (3.2–5.1)

40

0.041 ± 0.061

Active ( >5.1)

12

0.027 ± 0.032

P
0.435

Table 11. HAQ-DI values of the case group.
HAQ

n (%)

Light–medium

51 (72.9)

Medium–severe

18 (24.3

Severe

5 (6.7)

4. Discussion
Mean age was significantly lower in the case group
compared to the control group. This could be explained
by consecutive and randomized selection of the patients
who presented to our polyclinic to form the control group.
In the study performed on age- and sex-matched control
cases, it was demonstrated that the patients with RA had
a higher risk for CVDs, such as cardiovascular death,
ischemic heart diseases, and heart failure. Smoking is
another parameter of the FRS. Due to its inflammatory
effect, smoking is more damaging to the vascular wall of
patients with RA compared to a normal population (13).
In our study, the case group and the control group were
not significantly different in terms of smoking, and the
smoking rates were lower than in the overall population,
with rates of 20% and 26%, respectively.
In the multicenter study performed by Naranjo et
al., the prevalence of CVD was investigated in a total of
4363 RA patients from 15 countries (14). In this study, in
which mean age was 57 years, the prevalence of smoking
was found to be 43%. After an adjustment for age and sex,
smoking was shown to be correlated with a more serious
coronary arterial classification. In a large study performed
on patients who had experienced a myocardial infarction
(MI) for the first time and those who had not experienced
an MI after the diagnosis of RA, the patients who had
experienced MI were shown to exhibit an increased serum
level of cholesterol and low HDL cholesterol compared
to those who had not experienced an MI (15–17). These
undesirable lipid changes were thought to have emerged
at least 10 years before the onset of RA. Contrary to this
evidence, our study could not find a difference between
the 2 groups.
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The prevalence of diabetes, one of the traditional
risk factors for CVD, was found to be 8% in the study
performed by Naranjo et al., which is the same as our result
(8%). Systolic blood pressure is also among the traditional
risk factors for CVD. The prevalence of hypertension was
32% in the study performed by Naranjo et al. and 24% in
our study, being significantly higher compared to control
group. The fact that a moderate fall of blood pressure
reduces the risk for CVD is a well-known reality (18). In
our study, no statistically significant difference of FRS was
found between the 2 groups.
Aside from hypertension, there was no difference
between the groups regarding the traditional factors used
to calculate risk the absolute risk for CVD. As a result,
Framingham scores did not show any statistical difference.
In this regard, it would be more useful to include healthy
volunteers as the control group. In the case group of
our study, the prevalence of physical inactivity was not
significantly different compared to the control group.
Fourteen patients with RA and 10 controls were exercising
by walking 3 times per week. In RA, commonly observed
functional disability, joint pain, and stiffness may prevent
these patients from maintaining a regular exercise routine
(19).
BMI is used as to measure the amount of fat in the
body. In many previous studies, RA patients and controls
did not show a consistency in terms of BMI measurements
and it was demonstrated that BMI measurements could
be higher than, equal to, or lower than those obtained
in the controls (20). In our study, mean BMI value of the
subjects with RA and of the controls was 30 (overweight)
and, therefore, the difference between the 2 groups was not
statistically significant.
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When evaluating CVR in patients with RA, it was
shown that smoking and physical inactivity were important
risk factors (21). Contrary to our study, that study showed
that the patients with RA had a high absolute CVD risk,
independently from smoking, compared to the control
group. On the other hand, another study similar to ours
found that the risk for CVD was not different between the
patients with RA and those without RA. The magnitude
of CVR in patients with RA was reported to be likely
equal to that of the patients with type II DM and it was
recommended to give RA patients as much attention as
diabetics regarding CVR (22).
In our study, no significant correlation could be found
between 2 inflammatory markers, ESR and CRP, and the
FRS in the patients with RA. In a previous study, 151
patients with RA were examined and CRP levels were
found to be above 3 mg/L in 68% and above 10 mg/L in
25% of the patients. At the end of this study, it was reported
that CRP levels were correlated with high and very high
risk for a CV event. This was the case even in the majority
of the patients with RA, in whom the disease activity has
been thought to be kept under control. In our study, CRP
levels were above 3 mg/L in 35% and above 10 mg/L in
18% of the patients with RA. In our study, ESR levels were
significantly higher in the patients with RA compared to
the control group. A study showed that ESR levels were
higher in RA patients with atherosclerosis compared to
RA patients without atherosclerosis. This suggests that
both traditional risk factors and inflammation could play
a role in the development of CVD (23).
Disease duration and RF or anti-CCP positivity
are prognostic markers for the risk for CVD (24). In a
prospective study performed by Naz et al., a total of 1098
patients with inflammatory polyarthritis, in whom the
disease had begun before the age of 55, were evaluated
(25). With 5- and 10-year follow-ups for all reasons and
CV mortality, standardized mortality rate (SMR) was
calculated. It was detected that CV mortality was higher
in those with longer disease duration and in seropositive
patients (25). It is clear that long-term follow-up is needed
to determine the CV mortality of the case group in our
study. In a metaanalysis, SMR was found to be 1.2 in those
with a disease duration below 2 years and 1.9 in those with
established RA.
In our study, we found that the correlation between
therapy duration, disease duration, and FRS was not
statistically significant for the patients in the case
group. Efficient therapies may lead to an improvement
in physical inactivity and, therefore, may be helpful in

decreasing the risk for all important conditions such
as CVD, hypertension, obesity, and diabetes (26). In a
previous study, the effects of long-term disease-modifying
antirheumatic drug (DMARD) use on the disease activity
and endothelial function were investigated in patients with
early RA (ERA). Twenty-five ERA patients who had not
experienced any cardiovascular events were evaluated. It
was found that DMARDs significantly decreased DAS-28
scores (from 6.0 ± 0.8 to 2.0 ± 0.7) and increased coronary
flow reserve (27). In another study, following a 12-week
therapy with infliximab, a TNF-α blocker, a significant
decrease of DAS-28 scores and lowered ESR and CRP
levels were demonstrated (28,29). In our study, the mean
DAS-28 score was found to implicate moderate disease
activity in the patient group and its correlation with the
FRS was not shown to be statistically significant. All of
our patients were receiving DMARD therapy and, as the
disease activity scores were lower compared to above
mentioned studies, its correlation with the FRS was found
to be insignificant.
In a study performed by Radovitz et al. (17), the
authors investigated whether there was a correlation
between DAS-28 results and the occurrence of an MI in
the patients who had experienced an MI for the first time
after the diagnosis of RA and in the patients who had
never experienced an MI. In that study, the patients with
RA who had experienced an MI were found to have more
classical risk factors, but the 2 groups did not show any
significant difference in terms of disease activity.
In another study, blood pressure, arterial thickness,
lipids, glucose, ESR, and RF levels were determined and
their correlation with HAQ-DI results was investigated in
114 patients with RA, aged between 40 and 65, who had
no arterial disease. In that study, a positive correlation
was found between arterial thickness and HAQ-DI scores
(30). In our study, the mean HAQ-DI score was found to
be 0.642 ± 0.705 in the patients with RA and it was not
significantly correlated with the FRS.
Although the patients in the RA group had moderate
disease activity, their HAQ-DI scores indicated that they
were of a good functional status.
In conclusion, we could not find a significant
correlation between disease activity and functional
disability or CVR in our study. However, the literature
contains studies that demonstrated significant correlations
in this regard (31–33). To obtain more significant results,
long-term prospective studies with a larger sample size are
needed.
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